Surrozen Inc: Phase 1a Trial of Szn-043 Demonstrated Evidence of Target Engagement and Wnt-Pathway Mediated Pharmacodynamic Effects in Liver
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.